立体定向体部放疗(SBRT)治疗卵巢癌局限性区域复发的Ⅰ期试验
这项Ⅰ期3+3剂量递增研究纳入15例卵巢癌、输卵管癌或原发腹膜癌且总病灶≤3处的患者,SBRT剂量安全递增至第3剂量水平(30 Gy分3次),未出现剂量限制性毒性。1年局部控制率95%、无进展生存率45%、总生存率100%,全球健康状况/生活质量自基线维持。
要点
- SBRT剂量安全递增至30 Gy分3次,无剂量限制性毒性,无≥2级SBRT相关毒性。
- 1年局部控制率95%、无进展生存率45%、总生存率100%。
- 67%患者以SBRT替代全身治疗,其中70%在1年随访时仍未接受全身治疗。
核心结论
- 这项Ⅰ期试验提供初步证据,SBRT对卵巢癌局限性区域复发可能安全有效。
研究设计与样本
- Ⅰ期3+3剂量递增研究,纳入卵巢癌、输卵管癌或原发腹膜癌且总病灶≤3处的患者,共入组15例。
- 试验注册号:ClinicalTrials.gov NCT03325634。
主要发现
- SBRT剂量安全递增至第3剂量水平(30 Gy分3次),无剂量限制性毒性,无≥2级SBRT相关毒性。
- 1年局部控制率95%、无进展生存率45%、总生存率100%。
- 多数患者(67%)在研究中使用SBRT替代全身治疗,其中70%在1年随访时仍未接受全身治疗。
- SBRT完成后1年,全球健康状况/生活质量患者报告结局自基线值维持。
- 灌注影像显示,首分次SBRT后肿瘤血流量增加(p=0.02),自第1分次至SBRT后6周血流量(p<0.01)与血容量(p<0.01)下降。
关键数值与推荐
- SBRT剂量递增至第3剂量水平为30 Gy分3次,未出现剂量限制性毒性。
- 1年局部控制率95%、无进展生存率45%、总生存率100%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Radiation therapy is infrequently used in the treatment of advanced ovarian cancer due to the propensity for peritoneal spread and dose limitations of classical large field techniques. However, for patients with limited sites of recurrence, advanced radiation techniques such as SBRT may offer an effective treatment option. OBJECTIVE: To evaluate the safety, preliminary efficacy, quality-of-life outcomes, and tumor perfusion changes in patients with limited locoregional recurrences of ovarian cancer treated with SBRT. METHODS: Patients with ovarian, fallopian tube, or primary peritoneal cancer and ≤ 3 total sites of disease were eligible for this phase I 3 + 3 dose-escalation study. RESULTS: Fifteen patients were accrued and SBRT dose was safely escalated to dose-level 3 (30 Gy in 3 fractions) without dose-limiting toxicity. There were no grade 2 or higher SBRT-related toxicities. One-year LC, PFS, and OS were 95 %, 45 %, and 100 %, respectively. The majority of patients received SBRT on study in lieu of systemic therapy (67 %), and 70 % of these patients remained off systemic therapy at one-year follow-up. At one year after completion of SBRT, global health status/QOL patient reported outcomes were maintained from baseline values. Perfusion imaging demonstrated increases in tumor blood flow (p = 0.02) after delivery of the first fraction of SBRT and decreases in blood flow (p < 0.01) and blood volume (p < 0.01) from fraction 1 to 6 weeks after SBRT. CONCLUSIONS AND RELEVANCE: This Phase I trial offers preliminary evidence that SBRT can be safe and effective for limited site locoregional recurrences of ovarian cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03325634.
引用
- Robin TP, Hu J, Jones BL, et al. Phase I trial of stereotactic body radiation therapy (SBRT) for limited site locoregional recurrences of ovarian cancer. Gynecol Oncol. 2025. PMID: 40839922. doi:10.1016/j.ygyno.2025.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。